Selected article for: "adenoviral vector and mouse model"
Author: Kim, Eun; Erdos, Geza; Huang, Shaohua; Kenniston, Thomas; Falo, Louis D.; Gambotto, Andrea
Title: Preventative Vaccines for Zika Virus Outbreak: Preliminary Evaluation
  • Document date: 2016_10_3
    • ID: jzcyxjxt_2
    Snippet: The succesful development of flavivirus vaccines began 80 years ago in 1937 with the yellow fever YFV17D live-attenuated vaccine (Monath, 2008) . Since then, N 600 million people have been vaccinated, with 98% protection and a N10 year persistence of vaccine-induced immunity (Barrett and Teuwen, 2009 ). However, several severe adverse events associated with vaccine administration have been observed over the last 20 years. Thus, a purified, inacti.....
    Document: The succesful development of flavivirus vaccines began 80 years ago in 1937 with the yellow fever YFV17D live-attenuated vaccine (Monath, 2008) . Since then, N 600 million people have been vaccinated, with 98% protection and a N10 year persistence of vaccine-induced immunity (Barrett and Teuwen, 2009 ). However, several severe adverse events associated with vaccine administration have been observed over the last 20 years. Thus, a purified, inactivated vaccine has been recently developed and its testing results suggest good immunogenicity and tolerability (Monath et al., 2011) . A few weeks ago, two studies showing immunogenicity of a plasmid DNA or adenovirus (serotype 52) expressing virus-like particles in mice and non-human primates were published Abbink et al., 2016) . Here, to build on these initial findings to develop an effective ZIKV vaccine, we describe the development of a recombinant adenoviral vector expressing codon-optimized ZIKV E antigen and a subunit recombinant ZIKV E vaccine delivered transcutaneously by carboxymethyl cellulose (CMC) microneedle arrays (MNAs) (Bediz et al., 2014; Korkmaz et al., 2015) , investigate their ability to induce neutralizing immune responses, and assess their ability to passively protect against ZIKV challenge in a novel neonatal ZIKV infection mouse model.

    Search related documents:
    Co phrase search for related documents
    • adenoviral vector and immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • adenoviral vector and inactivated vaccine: 1, 2
    • adenoviral vector and mouse model: 1, 2, 3, 4, 5
    • adenoviral vector and non human primate: 1, 2
    • adenoviral vector and plasmid dna: 1
    • adenoviral vector and subunit recombinant: 1
    • adenoviral vector and vaccine induce: 1, 2, 3
    • adenovirus plasmid dna and plasmid dna: 1
    • adverse event and immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
    • adverse event and inactivated vaccine: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • adverse event and mouse model: 1, 2
    • adverse event and testing result: 1
    • adverse event and vaccine induce: 1
    • adverse event and yellow fever: 1
    • carboxymethyl cellulose and mouse model: 1
    • carboxymethyl cellulose and ZIKV challenge: 1